June 10, 2021 – Exeter, NH – Cytokind, Inc. (“Cytokind” or “company”) is announcing the first patient treated in the Adaptive Photo-Protection Trial which provides a phototherapy treatment to hospitalized COVID-19 patients. The trial is a collaboration with Louisiana State University Health Center (LSUHC), West Jefferson Medical Center (WJMC), Marrero, LA, and Cytokind.

“Treating the first patient has been a great team effort, including the clinical expertise of West Jefferson, researchers from LSUHC, and support from Cytokind. We are so excited to be moving a known safe and effective therapy from one field of medicine into the COVID-19 fight. It’s a real community effort,” said Frank Lau, MD, FACS, Professor of Clinical Surgery for LSUHC - New Orleans, and a Co-Principal Investigator of the clinical trial. “Together increased vaccination rates and the normal seasonal increase in sunlight that boosts our immune stability have helped reduced hospital caseloads and deaths across the country. This pandemic has also taught us to look out globally for what is coming next. This trial will help us be prepared for new variants and the seasonal fall-off in immune health later in the year. The team at West Jefferson is on the front lines of this research by providing this option to their patients.” Natural sunlight upon our skin provides the fuel necessary to stabilize our immune system and in parallel, elevates our natural vitamin D. Phototherapy, the delivery of a narrowband of ultraviolet B-Band light (NB-UVB), has been effectively used to calm overreactive immune disorders for decades in chronic and acute diseases such as psoriasis and Graft versus Host Disease, a deadly condition for bone marrow transplant patients. Phototherapy offers patients much more than vitamin D pills. West Jefferson is the first of up to 10 national sites. This trial is an example of LSUHC's commitment to be a hub for basic research and clinical innovation in the fight against COVID-19 and beyond. About Cytokind Inc. Cytokind, Inc. was founded to advance phototherapy with the rigor of a new cancer drug for COVID-19 and further clinical applications. For more information, please visit

About The Adaptive Photo-Protection Trial The Adaptive Photo-Protection Trial protocol, NCT # 04818970, is a randomized, placebo-controlled clinical trial for high-risk hospitalized COVID-19 patients. The trial will test whether the safe and effective treatment of phototherapy known to improve outcomes and survival in bone marrow transplant patients can do the same for high-risk COVID-19 patients. The level of vitamin D at the time of hospitalization is the number one predictor of COVID-19 outcomes. Our bodies normally produce our own vitamin D when a narrow band of ultraviolet light from the sun, NB-UVB, reaches our skin. Unfortunately, taking oral vitamin D supplements has not consistently improved outcomes. Phototherapy offers much more than supplements. By providing phototherapy to the bedside, NB-UVB will engage the body's naturally evolved

photo-immune pathway and produce dozens of immune balancing biomarkers and cytokines to promote immune stability, as well as to elevate vitamin D naturally. The trial will test whether phototherapy’s immune balancing effect will be sufficient to improve outcomes in these high-risk patients. Dr. Frank Lau, Professor of Clinical Surgery and Principal Investigator of the tissue engineering lab, and Dr. Robert Chugden, WJMC Chief Medical Officer, are the Co-Principal Investigators of this trial. Dr. Andrew DiNardo and his team at the Baylor School of Medicine-Infectious Disease lab will assess the treatment of phototherapy with the same OMICs-based rigor Baylor applies to new cancer drugs. Cytokind Inc: John MacMahon Co-Founder 103 Front Street Exeter, NH Tel: +1 603.264.7751 Email: Source: Cytokind, Inc.

Updated: Jan 21

Results Set the Stage for an Upcoming US Trial

January 6, 2021 – Morgan Hill, CA – Mitre Medical Corp., (“Mitre” or “company”) an early-stage medical device company developing the Mitral Touch®, a less invasive and safer approach to treat functional/secondary mitral valve regurgitation (FMR) and remodel the left ventricle (LV), announced the publication of the one-year results of the Mitral Touch in European patients. The article, entitled “First in Human Experience with an Epicardial Beating Heart Device for Secondary Mitral Regurgitation” by Thourani, et al. was published online December 14, 2020 on the Journal of Thoracic and Cardiovascular Surgery website.

The excerpt below from the discussion section of this peer-reviewed article speaks to the validation of the Mitral Touch in providing cardiac surgeons a beating heart option for these undertreated patients and the unprecedented reduction of these patients’ enlarged ventricles (LVESV reduction). Reducing the left ventricle interrupts the deadly heart failure cycle.

“Epicardial annuloplasty [by the Mitral Touch] provides the opportunity for

beating heart evaluation under TEE [ultrasound imaging] guidance of the

annuloplasty effect without an atriotomy. Avoiding the atriotomy and extended

bypass times may reduce recovery time, atrial arrhythmias, and embolization

when compared to standard mitral repair. This first-in-man study supports the

conclusion that the device improves MR and promotes LV remodeling in patients

with secondary MR.

The LV support provided by the epicardial annuloplasty device may explain the

improvement in LVESV remodeling (-31%) compared with the remodeling

improvement in CTSN Trials (-11.1% and -16.8). at 1-year.”

The structural heart market is seeing a very rapid uptake for new lower-risk devices that focus on specific patient populations. The Mitral Touch follows this strategy.

As lead author, Dr. Vinod H. Thourani, Marcus Chief of Cardiovascular Surgery for Piedmont Healthcare and the Marcus Heart Valve Center, noted, “We, as cardiac surgeons, are hungry for devices that are less invasive and improve outcomes. These results demonstrate that without opening the heart we can provide significant MR and left ventricular reduction. The bypass patients with secondary MR represent one of the largest unmet needs in our operating rooms. Presently, these patients go undertreated due to the invasive nature and limited benefit of standard annuloplasty. Confirming the Mitral Touch results in a larger patient trial would be a win for patients and a win for surgeons.”

MR Reduction + LV Reduction
Bypass + Concomitant Beating - Heart Epicardial Repair for Secondary MR

Image description: Epicardial beating heart MR repair can be successfully added to bypass

patients. The treatment resulted in acute reductions of MR and LVESV which were substituted for one year. The device adds a minimally invasive option for these undertreated patients.

Image Source: Thourani, V. (2020). First in Human Experience with an Epicardial Beating Heart Device For Secondary

Mitral Regurgitation [image] Journal of Thoracic and Cardiovascular Surgery.

“We are pleased that the results were recognized and accepted by the Journal of Thoracic and Cardiovascular Surgery as a valuable contribution to research in the field. The successful treatment of this first set of patients confirms that the Mitral Touch is a non-invasive solution to FMR and remodeling the LV and sets the stage for a larger study in the US,” stated John MacMahon, Chief Executive Officer of Mitre Medical.

About Mitre Medical Corp.

Mitre Medical Corp is an early-stage medical device company developing the Mitral Touch®, a less invasive and safer approach to treat functional mitral valve regurgitation (FMR) and remodel the left ventricle (LV) in patients with moderate to severe MR. Mitre Medical has the potential to be the new standard of care for FMR. For more information, please visit

Forward Looking Statements

This press release includes forward-looking statements including, but not limited to, statements related to the development of our technology, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties. Forward-looking statements speak only as of the date of this

press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

Mitre Medical Corp.:

John MacMahon

Chief Executive Officer

0 views0 comments